Navigation Links
PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust
Date:12/22/2011

SOUTH PLAINFIELD, N.J., Dec. 22, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria.  PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The discovery and development of new and novel antibiotics are urgently needed due to the increased frequency of bacterial resistance to marketed antibiotics in the hospital and community settings.  Hospital-acquired infections present a major threat to patient health and quality of life.  The Centers for Disease Control and Prevention estimates that approximately 1.7 million hospital-acquired bacterial infections cause or contribute to nearly 100,000 deaths in the United States each year with similar data reported from Europe.  Gram-negative bacteria are responsible for more than 30 percent of these infections.  The major concern with MDR Gram-negative bacteria is there are limited options to effectively treat them.

"We are honored to expand our relationship with the Wellcome Trust through this second award," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer at PTC Therapeutics.  "This funding will support our ongoing efforts to develop novel antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria."

PTC has identified a novel structural class of molecules that have potent activity against Gram-negative bacteria that are resistant to marketed antibiotics.  The anti-infective program at PTC is currently in lead optimization and advancing towards identifying a Development Candidate.

About Wellcome Trust

The Wellcome Trust is a global charity dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests. www.wellcome.ac.uk

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company that applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology, and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
2. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
3. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
4. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
5. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
6. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
7. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
8. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
9. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
10. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
11. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):